NPI registry status
Active
2026 NPPES data Hematology & Oncology Physician NPI 1689194904 MD
Verify on CMS → Zhengrui Xiao, MD
Hematology & Oncology Physician in Bronx, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,530 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
208
Medicare Part D claims · 46 beneficiaries · Hematology & Oncology Physician avg: 885
Generic prescribing
44%
generic claims · 56% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$4.5K
12 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Zhengrui Xiao, MD filed 208 Medicare Part D claims in 2024 as a Hematology & Oncology Physician in Bronx, New York, prescribing 44% generic.
- 208
- Part D claims, 2024
- 44%
- generic prescribing
- Likely
- board-certified (heuristic)
- ≥48th
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Zhengrui Xiao, MD
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1689194904), first enumerated 06/27/2017.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 208 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- Reported
Industry payment transparency
$4.5K in reported industry payments (12 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- State context
State board disciplinary context
New York statewide board action statistics are published annually — these figures describe aggregate state activity, not Zhengrui Xiao, MD's individual license status. Verify directly with the state medical board.
Source: NYSBPMC annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1689194904 · Hematology & Oncology Physician
NPI-10 · ENUM-RECENT · TAX-MID · RX-LIGHT · BOOK-LIGHT · PHOTO-ENUM
- NPI-10 1689194904
- ENUM-RECENT 2017
- TAX-MID 12K Hematology &
- RX-LIGHT 208
- BOOK-LIGHT 999 in New York
- PHOTO-ENUM Clinton Lewis · 2017
Zhengrui Xiao, MD's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
208 ≥ 48th percentile 48% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
✓
Board certification likely (heuristic, not verified)
Zhengrui Xiao, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Zhengrui Xiao, MD?
Quality data not reportedPrimary specialty
Hematology & Oncology Physician
Medicare Part D claims
208 76% vs specialty avg
Specialty distribution in New York
How Hematology & Oncology Physician compares to other specialties among New York providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Hematology & Oncology Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1689194904 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 06/27/2017 |
Hospital and facility affiliations
Facilities where Zhengrui Xiao, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Montefiore Medical Center
★★★☆☆ 3/5
Bronx, NY
Acute Care Hospitals
CMS CCN: 330059
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Zhengrui Xiao, MD. Source: openpaymentsdata.cms.gov.
Total received
$4.5K
Largest payer
GENZYME CORPORATION
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Zhengrui Xiao, MD. To verify Zhengrui Xiao, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
Zhengrui Xiao, MD - brand share 56.0%
Hematology & Oncology Physician average
56% brand-name claims vs 44% generic, on 208 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
208
Total Claims
$490K
Total Drug Cost
46
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 253.533
- Total Day Supply
- 7,274
- Brand vs Generic
- 56% brand / 44% generic
- Brand Drug Cost
- $486K
- Generic Drug Cost
- $4K
Patient Demographics
- Average Patient Age
- 71.9 years
- Avg HCC Risk Score
- 1.90
- Gender Split
- 61% female / 39% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Zhengrui Xiao, MD prescribes most
Top Medicare Part D drugs by claim count, 2024
- Eliquis
Eliquis
82 claims
- Hydroxyurea 19
Hydroxyurea
19 claims
- Imatinib Mesylate 14
Imatinib Mesylate
14 claims
- Mirtazapine 14
Mirtazapine
14 claims
- Promacta 14
Promacta
14 claims
- Xarelto 13
Xarelto
13 claims
| Drug | Claims |
|---|---|
| Eliquis Apixaban | 82 |
| Hydroxyurea | 19 |
| Imatinib Mesylate | 14 |
| Mirtazapine | 14 |
| Promacta Eltrombopag Olamine | 14 |
| Xarelto Rivaroxaban | 13 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How Zhengrui Xiao, MD fits within the Hematology & Oncology Physician landscape nationally.
11,530
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
885
Avg Claims per Provider
Zhengrui Xiao, MD's 208 claims are below the specialty average of 885.
Nationwide Hematology & Oncology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Xiao, both outside New York so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2017)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Hematology & Oncology Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Xiao.
One of 999 Hematology & Oncology Physician providers enrolled in New York, 5 are shown here.
Dr. Anum Aamir
M.D
Astoria, NY
Dr. Robert Abderhalden
MD
Painted Post, NY
Dr. Mohammad Maher Abdul Hay
MD
New York, NY
Dr. George Abraham
MD
Rochester, NY
Dr. Avram Abramowitz
M.D.
Fresh Meadows, NY
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Zhengrui Xiao, MD's specialty? ▼
Zhengrui Xiao, MD specializes in Hematology & Oncology Physician and practices in Bronx, New York. Credentials: MD.
How much does Zhengrui Xiao, MD prescribe under Medicare Part D? ▼
In 2024, Zhengrui Xiao, MD wrote 208 Medicare Part D claims totaling $490K in drug costs for 46 beneficiaries.
Where is Zhengrui Xiao, MD located? ▼
Zhengrui Xiao, MD is located at 1695 EASTCHESTER RD, Bronx, NY, 10461. Phone: (718) 405-8505.
What is Zhengrui Xiao, MD's NPI number? ▼
Zhengrui Xiao, MD's National Provider Identifier (NPI) is 1689194904, issued on 06/27/2017.
Does Zhengrui Xiao, MD prescribe more brand-name or generic drugs? ▼
Zhengrui Xiao, MD's prescribing is 56% brand-name and 44% generic drugs by claim count, with $486K in brand drug costs.
How many Hematology & Oncology Physician providers are there in the US? ▼
There are 11,530 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 885 Medicare Part D claims per year.
What drugs does Zhengrui Xiao, MD prescribe most often? ▼
Based on 2024 Medicare Part D data, Zhengrui Xiao, MD's most frequently prescribed drugs include Eliquis, Hydroxyurea, Imatinib Mesylate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Zhengrui Xiao, MD accept Medicare? ▼
Zhengrui Xiao, MD appears in CMS Medicare data with 208 Part D claims and 46 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Zhengrui Xiao, MD's credentials? ▼
Zhengrui Xiao, MD's NPI is 1689194904 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.